The company is focused on the discovery, development and commercialization of monoclonal antibodies
Personalized medicine
At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy
At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy.
MediaPharma's unique solution of developing drugs along with a companion diagnostic test offers combined advantages:
• selection of patients likely to respond to treatment;
• avoidance of toxicity for unresponsive patients;
• money and time saving;
• fast development of personalized therapeutics
Subscribe to Rss Feed
ShareMediaPharma S.r.l. P.IVA.: IT 02282760699 | Rea di Chieti: 166532
The information provided on www.mediapharma.it is designed to complement, not replace, the relationship between a patient and his/her own physician.
